Published in Cardiovasc Res on May 03, 2007
Diastolic intracellular calcium-membrane voltage coupling gain and postshock arrhythmias: role of purkinje fibers and triggered activity. Circ Res (2009) 1.96
Bidirectional ventricular tachycardia: ping pong in the His-Purkinje system. Heart Rhythm (2010) 1.94
Molecular and genetic basis of sudden cardiac death. J Clin Invest (2013) 1.23
Recent advances in the pathogenesis and drug action in periodic paralyses and related channelopathies. Front Pharmacol (2011) 1.05
Protein kinase A-dependent biophysical phenotype for V227F-KCNJ2 mutation in catecholaminergic polymorphic ventricular tachycardia. Circ Arrhythm Electrophysiol (2009) 0.94
Skeletal muscle channelopathies: new insights into the periodic paralyses and nondystrophic myotonias. Curr Opin Neurol (2009) 0.93
Delayed afterdepolarizations generate both triggers and a vulnerable substrate promoting reentry in cardiac tissue. Heart Rhythm (2015) 0.85
NCX is an important determinant for premature ventricular activity in a drug-induced model of Andersen-Tawil syndrome. Cardiovasc Res (2011) 0.80
Biophysical and molecular characterization of a novel de novo KCNJ2 mutation associated with Andersen-Tawil syndrome and catecholaminergic polymorphic ventricular tachycardia mimicry. Circ Cardiovasc Genet (2010) 0.79
Alternans of diastolic intracellular calcium elevation as the mechanism of bidirectional ventricular tachycardia in a rabbit model of Andersen-Tawil syndrome. Heart Rhythm (2010) 0.79
A Dynamical Threshold for Cardiac Delayed Afterdepolarization-Mediated Triggered Activity. Biophys J (2016) 0.78
Drug-induced Inhibition and Trafficking Disruption of ion Channels: Pathogenesis of QT Abnormalities and Drug-induced Fatal Arrhythmias. Curr Cardiol Rev (2016) 0.75
Electrophysiologic effects of the IK1 inhibitor PA-6 are modulated by extracellular potassium in isolated guinea pig hearts. Physiol Rep (2017) 0.75
Flecainide ameliorates arrhythmogenicity through NCX flux in Andersen-Tawil syndrome-iPS cell-derived cardiomyocytes. Biochem Biophys Rep (2017) 0.75
From vulnerable plaque to vulnerable patient: a call for new definitions and risk assessment strategies: Part I. Circulation (2003) 8.61
Electrocardiographic abnormalities and sudden death in myotonic dystrophy type 1. N Engl J Med (2008) 4.65
From vulnerable plaque to vulnerable patient: a call for new definitions and risk assessment strategies: Part II. Circulation (2003) 3.94
What causes sudden death in heart failure? Circ Res (2004) 3.44
Mechanisms of sudden cardiac death. J Clin Invest (2005) 2.90
Fragmented QRS on a 12-lead ECG: a predictor of mortality and cardiac events in patients with coronary artery disease. Heart Rhythm (2007) 2.37
Inaccessibility to quinidine therapy is about to get worse. J Am Coll Cardiol (2013) 2.12
The QT syndromes: long and short. Lancet (2008) 2.10
Introduction: eligibility recommendations for competitive athletes with cardiovascular abnormalities-general considerations. J Am Coll Cardiol (2005) 1.92
Bethesda Conference #36 and the European Society of Cardiology Consensus Recommendations revisited a comparison of U.S. and European criteria for eligibility and disqualification of competitive athletes with cardiovascular abnormalities. J Am Coll Cardiol (2008) 1.80
Role of the autonomic nervous system in modulating cardiac arrhythmias. Circ Res (2014) 1.64
Fragmented QRS as a marker of conduction abnormality and a predictor of prognosis of Brugada syndrome. Circulation (2008) 1.62
Continuous low-level vagus nerve stimulation reduces stellate ganglion nerve activity and paroxysmal atrial tachyarrhythmias in ambulatory canines. Circulation (2011) 1.58
Spontaneous electrocardiogram alterations predict ventricular fibrillation in Brugada syndrome. Heart Rhythm (2011) 1.51
Heart rate-corrected QT interval in men increases during winter months. Heart Rhythm (2006) 1.48
Severity of cardiac conduction involvement and arrhythmias in myotonic dystrophy type 1 correlates with age and CTG repeat length. J Cardiovasc Electrophysiol (2002) 1.44
Fragmented QRS: a predictor of mortality and sudden cardiac death. Heart Rhythm (2008) 1.38
Thoracic spinal cord stimulation reduces the risk of ischemic ventricular arrhythmias in a postinfarction heart failure canine model. Circulation (2005) 1.34
Task Force 7: arrhythmias. J Am Coll Cardiol (2005) 1.30
Risk stratification for arrhythmic sudden cardiac death: identifying the roadblocks. Circulation (2011) 1.27
Update of the guidelines on sudden cardiac death of the European Society of Cardiology. Eur Heart J (2003) 1.21
Pulseless electric activity: definition, causes, mechanisms, management, and research priorities for the next decade: report from a National Heart, Lung, and Blood Institute workshop. Circulation (2013) 1.18
Risk stratification for sudden cardiac death: a plan for the future. Circulation (2014) 1.14
Spinal cord stimulation improves ventricular function and reduces ventricular arrhythmias in a canine postinfarction heart failure model. Circulation (2009) 1.14
Cardiology patient page. Catheter ablation of arrhythmias. Circulation (2002) 1.12
Prophylactic lidocaine in acute myocardial infarction: resurface or reburial? Am J Cardiol (2004) 1.06
Sudden cardiac death: better understanding of risks, mechanisms, and treatment. Circulation (2006) 1.05
Safety of sports for athletes with implantable cardioverter-defibrillators: results of a prospective, multinational registry. Circulation (2013) 1.04
Implantable cardioverter defibrillator utilization based on discharge diagnoses from Medicare and managed care patients. J Cardiovasc Electrophysiol (2002) 1.04
Temperature modulation of ventricular arrhythmogenicity in a canine tissue model of Brugada syndrome. Heart Rhythm (2006) 1.01
Spontaneous adverse event reports of serious ventricular arrhythmias, QT prolongation, syncope, and sudden death in patients treated with cisapride. J Cardiovasc Pharmacol Ther (2002) 1.01
Effects of thoracic spinal cord stimulation on cardiac autonomic regulation of the sinus and atrioventricular nodes. J Cardiovasc Electrophysiol (2002) 1.01
Mechanisms of sinoatrial node dysfunction in a canine model of pacing-induced atrial fibrillation. Heart Rhythm (2009) 1.00
Functional and transmural modulation of M cell behavior in canine ventricular wall. Am J Physiol Heart Circ Physiol (2004) 0.99
[Guidelines for management of patients with ventricular arrhythmias and the prevention of sudden cardiac death. Executive summary]. Rev Esp Cardiol (2006) 0.96
Brugada syndrome: insights of ST elevation, arrhythmogenicity, and risk stratification from experimental observations. Heart Rhythm (2009) 0.96
Eligibility and Disqualification Recommendations for Competitive Athletes With Cardiovascular Abnormalities: Task Force 9: Arrhythmias and Conduction Defects: A Scientific Statement From the American Heart Association and American College of Cardiology. J Am Coll Cardiol (2015) 0.94
Epicardial but not endocardial premature stimulation initiates ventricular tachyarrhythmia in canine in vitro model of long QT syndrome. Heart Rhythm (2004) 0.93
Attitudes of law enforcement officers regarding automated external defibrillators. Acad Emerg Med (2002) 0.93
Use of nonantiarrhythmic drugs for prevention of sudden cardiac death. J Cardiovasc Electrophysiol (2003) 0.92
A history of heart failure predicts arrhythmia treatment efficacy: data from the Antiarrythmics versus Implantable Defibrillators (AVID) study. Am Heart J (2006) 0.91
Task Force 10: automated external defibrillators. J Am Coll Cardiol (2005) 0.91
Short-term rapid atrial pacing produces electrical remodeling of sinus node function in humans. J Cardiovasc Electrophysiol (2002) 0.89
Optical mapping of the functional reentrant circuit of ventricular tachycardia in acute myocardial infarction. Heart Rhythm (2004) 0.89
Mortality as an endpoint in atrial fibrillation. Heart Rhythm (2004) 0.88
Intrathecal clonidine reduces the incidence of ischemia-provoked ventricular arrhythmias in a canine postinfarction heart failure model. Heart Rhythm (2005) 0.88
Eligibility and Disqualification Recommendations for Competitive Athletes With Cardiovascular Abnormalities: Task Force 10: The Cardiac Channelopathies: A Scientific Statement From the American Heart Association and American College of Cardiology. J Am Coll Cardiol (2015) 0.88
Epicardial ablation eliminates ventricular arrhythmias in an experimental model of Brugada syndrome. Heart Rhythm (2009) 0.87
Device therapy to modulate the autonomic nervous system to treat heart failure. Curr Cardiol Rep (2012) 0.87
Antiarrhythmic and nonantiarrhythmic drugs for sudden cardiac death prevention. J Cardiovasc Pharmacol (2010) 0.86
T wave alternans in an in vitro canine tissue model of Brugada syndrome. Am J Physiol Heart Circ Physiol (2006) 0.86
Genes and cardiac repolarization: the challenge ahead. Circulation (2005) 0.85
Repolarization heterogeneity in the right ventricular outflow tract: correlation with ventricular arrhythmias in Brugada patients and in an in vitro canine Brugada model. Heart Rhythm (2008) 0.85
Clinical pathways based on integrative medicine in chinese hospitals improve treatment outcomes for patients with acute myocardial infarction: a multicentre, nonrandomized historically controlled trial. Evid Based Complement Alternat Med (2012) 0.84
Kb-R7943 prevents acute, atrial fibrillation-induced shortening of atrial refractoriness in anesthetized dogs. Circulation (2002) 0.84
Ischemic ventricular arrhythmias during heart failure: a canine model to replicate clinical events. Heart Rhythm (2005) 0.82
Seasonal variation of mortality in the Antiarrhythmics Versus Implantable Defibrillators (AVID) study registry. Heart Rhythm (2004) 0.82
Quinidine, a life-saving medication for Brugada syndrome, is inaccessible in many countries. J Am Coll Cardiol (2013) 0.82
Rate-dependent [K+](o) accumulation in canine right atria in vivo: electrophysiological consequences. Am J Physiol Heart Circ Physiol (2002) 0.82
Coronary occlusion and reperfusion promote early afterdepolarizations and ventricular tachycardia in a canine tissue model of type 3 long QT syndrome. Am J Physiol Heart Circ Physiol (2005) 0.82
Mechanisms of disease: new mechanisms of antiarrhythmic actions. Nat Clin Pract Cardiovasc Med (2004) 0.82
Enhanced sensitivity to drug-induced QT interval lengthening in patients with heart failure due to left ventricular systolic dysfunction. J Clin Pharmacol (2011) 0.81
Differences in arrhythmogenicity between the canine right ventricular outflow tract and anteroinferior right ventricle in a model of Brugada syndrome. Heart Rhythm (2006) 0.81
Analysis of action potentials in the canine ventricular septum: no phenotypic expression of M cells. Cardiovasc Res (2007) 0.81
Prior ischemia enhances arrhythmogenicity in isolated canine ventricular wedge model of long QT 3. Cardiovasc Res (2004) 0.81
Early afterdepolarizations, U waves, and torsades de pointes. Circulation (2002) 0.81
Sudden death predictors: an inflammatory association. Circulation (2002) 0.81
Mechanisms underlying atrioventricular nodal conduction and the reentrant circuit of atrioventricular nodal reentrant tachycardia using optical mapping. J Cardiovasc Electrophysiol (2002) 0.80
The role of coronary sinus musculature in the induction of atrial fibrillation. Heart Rhythm (2011) 0.80